Corcept Therapeutics (CORT)
NASDAQ:CORT
Want to see CORT full AI Analyst Report?
CORT Stock Chart & Stats
$46.16
$0.08(0.16%)
At close: 4:00 PM EST
$46.16
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$28.66 - $91.00
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.19M
Market Cap
$8.90B
Enterprise Value$7.36B
Total Cash (Recent Filing)$338.18M
Total Debt (Recent Filing)$9.64M
Price to Earnings (P/E)180.8
Beta0.47
Next Earnings
Aug 05, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding107,351,590
10 Day Avg. Volume974,108
30 Day Avg. Volume1,188,074
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue9.57
Enterprise Value/Gross Profit9.74
Enterprise Value/Ebitda542.91
Forecast
1Y Price Target
$97.50Price Target Upside111.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.59
Revenue Forecast (FY)$976.58M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthCorcept's large cash balance and extremely low leverage provide durable financial flexibility to fund Lifyorli's launch, expand specialty pharmacy capacity, and support multiple late-stage trials without immediate capital raises. That runway cushions operating swings and underpins multi‑quarter execution.
Very High Gross Margins And Cash ConversionNear‑100% gross margins reflect the productized, low‑variable‑cost nature of Corcept's marketed drugs, enabling strong incremental operating leverage. Historically free cash flow has tracked earnings, supporting reinvestment in commercialization and R&D and improving resilience to revenue variability.
Pipeline Diversification And Regulatory MomentumLifyorli's FDA approval and ROSELLA's mortality benefit materially diversify Corcept beyond its endocrine franchise into oncology, creating a second durable revenue engine. Inclusion in guidelines and rapid early uptake support sustainable market expansion and multiple future readouts that can compound long‑term growth.
Bears Say
Profitability CompressionRising operating costs from product launches and commercialization investments have materially compressed margins and produced a near‑term net loss. If elevated spending persists without commensurate revenue catch‑up, cash generation and return metrics could remain pressured over the coming quarters.
Operational Scaling And Revenue Recognition RiskTransitioning patients to a new specialty pharmacy generated prior‑authorization delays and suppressed near‑term revenue. Scaling the network is required to support rising volumes; failure to expand operations timely could prolong revenue lags, impair adherence, and increase operating costs over multiple quarters.
Prolonged Legal UncertaintyAn amended whistleblower suit, even without DOJ intervention, creates ongoing legal exposure and potential distraction. Litigation can impose material defense costs, reputational risk, and reimbursement scrutiny that persist over an extended timeline, complicating planning and partnerships.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $28.66 and its highest was $91.00 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $8.90B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 51 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.19.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.01.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 107,351,590 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went up 10.533%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.50 (111.22% Upside)
$97.50 (111.22% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 127.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.47%
12-Months-Change
Fundamentals
Return on Equity
7.50%
Trailing 12-Months
Asset Growth
-3.73%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
CORT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum driven by major clinical and regulatory milestones (Lifyorli FDA approval with a significant survival benefit, landmark CATALYST and MOMENTUM findings that broaden the addressable market, robust patient and prescriber growth, raised 2026 guidance, and compelling ALS and MASH data). Near-term negatives include a Q1 earnings swing to a net loss, temporary revenue headwinds from insurance reauthorizations and a pharmacy-transition backlog, and tolerability-related discontinuations in DAZALS that require mitigation. On balance, the company demonstrated durable commercial traction, an expanding pipeline with high-impact results, and clear plans to address operational issues, leading to a favorable outlook.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$97.50
▲(111.22% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
10.90% Insiders
15.13% Mutual Funds
16.58% Other Institutional Investors
35.98% Public Companies and
Individual Investors